Katharina Büsch1,2,3, Jesper Waldenström4, Martin Lagging4, Soo Aleman5,6, Ola Weiland7, Jan Kövamees1, Ann-Sofi Duberg8, Jonas Söderholm1,3. 1. a AbbVie AB , Stockholm , Sweden. 2. b Department of Medicine , Karolinska Institutet , Stockholm , Sweden. 3. h Department of Laboratory Medicine, Division of Clinical Microbiology , Karolinska Institutet, Karolinska University Hospital , Stockholm , Sweden. 4. c Department of Infectious Medicine , Institute of Biomedicine, Sahlgrenska Academy at the University of Gothenburg , Gothenburg , Sweden. 5. d Department of Infectious Diseases , Karolinska Institutet, Karolinska University Hospital , Stockholm , Sweden. 6. e Department of Gastroenterology and Hepatology , Karolinska Institutet, Karolinska University Hospital , Stockholm , Sweden. 7. f Department of Medicine Huddinge, Division of Infectious Diseases , Karolinska Institutet, Karolinska University Hospital , Stockholm , Sweden. 8. g Department of Infectious Diseases, Faculty of Medicine and Health , Örebro University , Örebro , Sweden.
Abstract
PURPOSE: The aim of this study was to estimate the prevalence of physician-diagnosed and registered chronic hepatitis C (CHC), and to estimate the reported frequencies of Charlson comorbidities compared with matched comparators from the general population. MATERIALS AND METHODS: Patients were identified according to ICD codes for CHC in the Swedish National Patient Register (1997-2013). Prevalence was estimated according to different patient identification algorithms and for different subgroups. Charlson comorbidities were ascertained from the same register and compared with age/sex/county of residence matched general population comparators. RESULTS: A total of 34,633 individuals with physician-diagnosed CHC were alive in Sweden in 2013 (mean age, 49 years; 64% men), corresponding to a physician-diagnosed prevalence of 0.36%. The prevalence varied by case definition (0.22%-0.36%). The estimate dropped to 0.14% for monitored CHC disease (defined as ≥1 CHC-related visit in 2013). Overall, 41.3% of the CHC patients had ≥1 physician-registered Charlson comorbidity; the most common was liver diseases (22.1%). Compared with matched comparators from the general population (n = 171,338), patients with CHC had more physician-diagnosed and registered diseases such as chronic pulmonary disease (10.2% vs. 4.0%), diabetes (10.6% vs. 5.5%) and liver-related cancer (1.3% vs. 0.2%; all p < .01). No information on behavioural factors, such as smoking, alcohol consumption or on-going illicit drug use, was available. CONCLUSION: The physician-diagnosed prevalence of CHC was slightly lower than previously reported estimates, and varied by case definition. The additional comorbidities observed in the CHC group should be taken into consideration, as these comorbidities add to the disease burden.
PURPOSE: The aim of this study was to estimate the prevalence of physician-diagnosed and registered chronic hepatitis C (CHC), and to estimate the reported frequencies of Charlson comorbidities compared with matched comparators from the general population. MATERIALS AND METHODS:Patients were identified according to ICD codes for CHC in the Swedish National Patient Register (1997-2013). Prevalence was estimated according to different patient identification algorithms and for different subgroups. Charlson comorbidities were ascertained from the same register and compared with age/sex/county of residence matched general population comparators. RESULTS: A total of 34,633 individuals with physician-diagnosed CHC were alive in Sweden in 2013 (mean age, 49 years; 64% men), corresponding to a physician-diagnosed prevalence of 0.36%. The prevalence varied by case definition (0.22%-0.36%). The estimate dropped to 0.14% for monitored CHC disease (defined as ≥1 CHC-related visit in 2013). Overall, 41.3% of the CHCpatients had ≥1 physician-registered Charlson comorbidity; the most common was liver diseases (22.1%). Compared with matched comparators from the general population (n = 171,338), patients with CHC had more physician-diagnosed and registered diseases such as chronic pulmonary disease (10.2% vs. 4.0%), diabetes (10.6% vs. 5.5%) and liver-related cancer (1.3% vs. 0.2%; all p < .01). No information on behavioural factors, such as smoking, alcohol consumption or on-going illicit drug use, was available. CONCLUSION: The physician-diagnosed prevalence of CHC was slightly lower than previously reported estimates, and varied by case definition. The additional comorbidities observed in the CHC group should be taken into consideration, as these comorbidities add to the disease burden.
Entities:
Keywords:
Comorbidities; Sweden; hepatitis C; matched general population comparators; prevalence
Authors: P Frisk; K Aggefors; T Cars; N Feltelius; S A Loov; B Wettermark; O Weiland Journal: Eur J Clin Pharmacol Date: 2018-04-09 Impact factor: 2.953
Authors: Katharina Büsch; Fredrik Hansson; Michelle Holton; Martin Lagging; Johan Westin; Jan Kövamees; Matti Sällberg; Jonas Söderholm Journal: BMJ Open Date: 2020-09-02 Impact factor: 2.692